StockData
AtriCure, Inc. logo

AtriCure, Inc. (ATRC) stock

ATRCNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 12/30893% above fair value
$55.02−0.29 (-0.52%)

Close on Nov 17, 2026Market cap $2.80BP/E 262.0Yield –

AtriCure r&d expenses

Research and development expenses are spending on new products and technology.

AtriCure's R&D Expenses for the twelve months ending Jun 30, 2026 was $98.03M, down 9.0% year over year. For fiscal 2025 it was $99.21M, up 3.2% from the year before. Over ten years it grew 14.4% a year on average. The highest annual figure on record is $99.21M in fiscal 2025.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$99.21M+3.2%
FY2024Dec 31, 2024$96.18M+30.1%
FY2023Dec 31, 2023$73.92M+28.9%
FY2022Dec 31, 2022$57.34M+18.2%
FY2021Dec 31, 2021$48.51M+12.6%
FY2020Dec 31, 2020$43.07M+4.5%
FY2019Dec 31, 2019$41.23M+18.7%
FY2018Dec 31, 2018$34.72M+1.7%
FY2017Dec 31, 2017$34.14M-4.7%
FY2016Dec 31, 2016$35.82M+39.2%
FY2015Dec 31, 2015$25.74M+38.4%
FY2014Dec 31, 2014$18.60M+38.4%
FY2013Dec 31, 2013$13.44M+10.6%
FY2012Dec 31, 2012$12.15M+2.4%
FY2011Dec 31, 2011$11.86M+2.8%
FY2010Dec 31, 2010$11.53M+1.0%
FY2009Dec 31, 2009$11.41M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$26.40M-9.8%
Q1 FY2026Mar 31, 2026$24.24M+7.6%
Q4 FY2025Dec 31, 2025$24.51M-29.9%
Q3 FY2025Sep 30, 2025$22.89M+9.2%
Q2 FY2025Jun 30, 2025$29.28M+43.4%
Q1 FY2025Mar 31, 2025$22.53M+13.5%
Q4 FY2024Dec 31, 2024$34.96M+68.1%
Q3 FY2024Sep 30, 2024$20.96M+3.0%
Q2 FY2024Jun 30, 2024$20.42M+17.1%
Q1 FY2024Mar 31, 2024$19.85M+29.5%
Q4 FY2023Dec 31, 2023$20.80M+51.3%
Q3 FY2023Sep 30, 2023$20.35M+34.2%
Q2 FY2023Jun 30, 2023$17.44M+17.9%
Q1 FY2023Mar 31, 2023$15.33M+12.5%
Q4 FY2022Dec 31, 2022$13.75M-0.4%
Q3 FY2022Sep 30, 2022$15.17M+34.4%
Q2 FY2022Jun 30, 2022$14.79M+21.3%
Q1 FY2022Mar 31, 2022$13.63M+21.5%
Q4 FY2021Dec 31, 2021$13.81M+27.0%
Q3 FY2021Sep 30, 2021$11.28M+6.7%
Q2 FY2021Jun 30, 2021$12.20M+21.5%
Q1 FY2021Mar 31, 2021$11.22M-3.2%
Q4 FY2020Dec 31, 2020$10.87M-17.0%
Q3 FY2020Sep 30, 2020$10.58M+4.2%
Q2 FY2020Jun 30, 2020$10.04M+2.4%
Q1 FY2020Mar 31, 2020$11.59M+41.7%
Q4 FY2019Dec 31, 2019$13.10M+54.9%
Q3 FY2019Sep 30, 2019$10.15M+18.7%
Q2 FY2019Jun 30, 2019$9.80M+13.3%
Q1 FY2019Mar 31, 2019$8.18M-9.7%
Q4 FY2018Dec 31, 2018$8.46M+9.5%
Q3 FY2018Sep 30, 2018$8.56M+7.4%
Q2 FY2018Jun 30, 2018$8.66M-2.8%
Q1 FY2018Mar 31, 2018$9.06M-5.2%
Q4 FY2017Dec 31, 2017$7.72M-21.7%
Q3 FY2017Sep 30, 2017$7.97M-3.7%
Q2 FY2017Jun 30, 2017$8.91M–
Q1 FY2017Mar 31, 2017$9.55M–
Q4 FY2016Dec 31, 2016$9.87M–
Q3 FY2016Sep 30, 2016$8.27M–

More AtriCure figures

See a number that looks wrong?